| Mango Medical | |
|
64-1032 Mamalahoa Hwy Suite 306 Kamuela HI 96743 | |
| (808) 769-5010 | |
| (808) 769-5208 |
| Full Name | Mango Medical |
|---|---|
| Speciality | Family Medicine |
| Location | 64-1032 Mamalahoa Hwy, Kamuela, Hawaii |
| Authorized Official Name and Position | Timothy Duerler (PRESIDENT) |
| Authorized Official Contact | 8083516836 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mango Medical 64-1032 Mamalahoa Hwy Suite 306 Kamuela HI 96743 Ph: (808) 769-5010 | Mango Medical 64-1032 Mamalahoa Hwy Suite 306 Kamuela HI 96743 Ph: (808) 769-5010 |
| NPI Number | 1376837997 |
|---|---|
| Provider Enumeration Date | 05/31/2011 |
| Last Update Date | 09/25/2015 |
| Medicare PECOS PAC ID | 2062680861 |
|---|---|
| Medicare Enrollment ID | O20110721000841 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376837997 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | (* (Not Available)) | Secondary |
| Provider Name | Adam J Gratz |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1598895351 PECOS PAC ID: 9335153725 Enrollment ID: I20060206000861 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Cindy O Cohen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538117163 PECOS PAC ID: 3779599758 Enrollment ID: I20070206000580 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Amy J Duerler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184606899 PECOS PAC ID: 0446344105 Enrollment ID: I20080423000605 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Timothy S Duerler |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053433441 PECOS PAC ID: 0547325854 Enrollment ID: I20090223000044 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Joshua Lessard-chaudoin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437588969 PECOS PAC ID: 0244462695 Enrollment ID: I20140417000360 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Judith Casarella |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528127750 PECOS PAC ID: 8820002454 Enrollment ID: I20150410002042 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | James Robert Brooks |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1700928082 PECOS PAC ID: 8729398920 Enrollment ID: I20151029002273 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Russell Parker |
|---|---|
| Provider Type | Practitioner - Osteopathic Manipulative Medicine |
| Provider Identifiers | NPI Number: 1023167947 PECOS PAC ID: 5294992228 Enrollment ID: I20170130001471 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | James Gilley |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1881602787 PECOS PAC ID: 2365414125 Enrollment ID: I20170130001666 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Carly Kaleo Correa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992206973 PECOS PAC ID: 4587925417 Enrollment ID: I20180309001124 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Amanda M Drake |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285382168 PECOS PAC ID: 4981091741 Enrollment ID: I20220425002355 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
| Provider Name | Jenifer P. Aaronson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053607119 PECOS PAC ID: 5799007985 Enrollment ID: I20221129002315 |
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
News Archive
Studies have shown that obese children tend to have more muscle, but recent University of Georgia research on the muscle and bone relationship shows that excess body fat may compromise other functions in their bodies, such as bone growth.
Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.
Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
TDR, in partnership with the WHO Global Tuberculosis Programme, has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care.
› Verified 6 days ago
Ron D Ah Loy Md Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 64-5188 Kinohou St, Kamuela, HI 96743 Phone: 808-887-0600 Fax: 808-887-6699 | |
Paniolo Pediatric And Family Medicine Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 64-1032 Mamalahoa Hwy Ste 204, Kamuela, HI 96743 Phone: 808-887-6543 Fax: 808-887-6294 | |
Mango Foundation, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 64-1032 Mamalahoa Hwy, Suite 306, Kamuela, HI 96743 Phone: 808-769-5010 | |
North Hawaii Hospitalist Physicians Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 65-1158 Mamalahoa Hwy Ste 27b, Kamuela, HI 96743 Phone: 808-887-2808 Fax: 808-887-2838 | |
Hamakua Health Center, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 65-1190 Mamalahoa Hwy, Suites 1, 2, 3 And 12, Kamuela, HI 96743 Phone: 808-775-7204 Fax: 808-775-9404 | |
Kaiser Hawaii Mobile Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 67-1185 Mamalahoa Hwy Unit A, Waimea Clinic, Kamuela, HI 96743 Phone: 808-881-4500 | |
Waikoloa Medical Arts, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 64-1035 Mamalahoa Hwy, Suite K, Kamuela, HI 96743 Phone: 808-883-9785 Fax: 808-883-9783 |